Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review

Denise Fabian; Maria del Pilar Guillermo Prieto Eibl; Iyad Alnahhas; Nikhil Sebastian; Pierre Giglio; Vinay Puduvalli; Javier Gonzalez; Joshua D. Palmer

doi:10.3390/cancers11020174

Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review

Denise Fabian, Maria del Pilar Guillermo Prieto Eibl, Iyad Alnahhas, Nikhil Sebastian, Pierre Giglio, Vinay Puduvalli, Javier Gonzalez, Joshua D. Palmer

Research output: Contribution to journal › Review article › peer-review

146 Scopus citations

Abstract

Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

Original language	English (US)
Article number	174
Journal	Cancers
Volume	11
Issue number	2
DOIs	https://doi.org/10.3390/cancers11020174
State	Published - Feb 2019
Externally published	Yes

Keywords

GBM
Glioblastoma
TTF
Tumor treating fields

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers11020174

Cite this

@article{a955588bc3b54564b57fc1f6df9034e1,

title = "Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review",

abstract = "Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.",

keywords = "GBM, Glioblastoma, TTF, Tumor treating fields",

author = "Denise Fabian and Eibl, {Maria del Pilar Guillermo Prieto} and Iyad Alnahhas and Nikhil Sebastian and Pierre Giglio and Vinay Puduvalli and Javier Gonzalez and Palmer, {Joshua D.}",

note = "Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2019",

month = feb,

doi = "10.3390/cancers11020174",

language = "English (US)",

volume = "11",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF)

T2 - A review

AU - Fabian, Denise

AU - Eibl, Maria del Pilar Guillermo Prieto

AU - Alnahhas, Iyad

AU - Sebastian, Nikhil

AU - Giglio, Pierre

AU - Puduvalli, Vinay

AU - Gonzalez, Javier

AU - Palmer, Joshua D.

PY - 2019/2

Y1 - 2019/2

N2 - Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

AB - Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

KW - GBM

KW - Glioblastoma

KW - TTF

KW - Tumor treating fields

UR - http://www.scopus.com/inward/record.url?scp=85062386864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062386864&partnerID=8YFLogxK

U2 - 10.3390/cancers11020174

DO - 10.3390/cancers11020174

M3 - Review article

C2 - 30717372

AN - SCOPUS:85062386864

SN - 2072-6694

VL - 11

JO - Cancers

JF - Cancers

IS - 2

M1 - 174

ER -

Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this